老年人中数字技术使用和痴呆症:活动限制的调节作用
Jiao Yu1, Wenxuan Huang2, Roland J Thorpe3
1School of Public Health, Yale University, New Haven, Connecticut, United States.
概括
与数字技术的接触与老年人痴呆的风险较低有关. 这种好处对活动限制的人来说更为明显,这表明技术可以帮助管理残疾和痴呆症.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 痴呆症是一个重大的公共卫生挑战,特别是对老年人来说.
- 数字技术的使用在老年人中越来越普遍,但其对痴呆风险的影响尚未完全理解.
- 活动限制可能会影响健康结果,并可能与技术参与互动.
研究的目的:
- 调查数字技术使用与美国老年人痴呆风险之间的纵向关联.
- 评估活动限制 (流动性,自我照顾,家庭) 对这种关联的调节作用.
主要方法:
- 利用了来自全国健康和衰老趋势研究 (NHATS) 的12个数据波,其中有5,469名参与者.
- 雇佣混合效应订购后勤模型和反向概率加权 (IPW) 来分析这种关系.
- 研究了特定活动限制对技术使用和痴呆风险的适度效应.
主要成果:
- 日常和数字健康技术的使用与没有痴呆的可能性更高,可能和可能痴呆的可能性更低.
- 活动限制显著缓和了这些协会.
- 数字技术使用对痴呆症的保护性关联在活动限制的老年人中更强.
结论:
- 数字技术参与是一种可扩展的策略,可减轻老年人痴呆风险.
- 政策应侧重于包容性数字计划,以提高可访问性和数字素养.
- 数字参与在解决残疾和痴呆症的双重负担方面表现有前途.
更多相关视频
11:21Methodology for Establishing a Community-Wide Life Laboratory for Capturing Unobtrusive and Continuous Remote Activity and Health Data
Published on: July 27, 2018
8.6K
08:45Measuring the Kinematics of Daily Living Movements with Motion Capture Systems in Virtual Reality
Published on: April 5, 2018
8.0K
相关概念视频
Cognitive Development During Adulthood
757
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
757
Dementia
503
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
503
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Drug Dosing: Geriatric Patients
215
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
215
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
